Literature DB >> 15664228

T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors.

Nasser Semmo1, Eleanor Barnes, Craig Taylor, John Kurtz, Gillian Harcourt, Neil Smith, Paul Klenerman.   

Abstract

Blood donors are routinely screened for hepatitis C virus infection. Some individuals have weak or restricted virus-specific antibody responses, and are classed as indeterminate. Such donors are almost always negative for viral RNA in blood. We postulated that previous transient virus exposure might account for some of these cases. With sensitive ex-vivo analyses of T-cell responses, we identified virus-specific responses in 15 of 30 indeterminate blood donors tested, compared with none in controls (p=0.0013). Additionally, these responses were typically focused on core-derived peptides. These findings suggest previous exposure to the virus in many indeterminate blood donors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664228     DOI: 10.1016/S0140-6736(05)17787-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  Impact of host responses on control of hepatitis C virus infection in Chinese blood donors.

Authors:  Tingting Li; Zixuan Chen; Jinfeng Zeng; Jingang Zhang; Wenjing Wang; Ling Zhang; Xin Zheng; Lifang Shuai; Paul Klenerman; Jean-Pierre Allain; Chengyao Li
Journal:  Biochem Biophys Res Commun       Date:  2011-10-29       Impact factor: 3.575

Review 2.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  New perspectives in occult hepatitis C virus infection.

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

4.  Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection.

Authors:  Juan A Quiroga; Inmaculada Castillo; Margarita Pardo; Elena Rodríguez-Iñigo; Vicente Carreño
Journal:  J Clin Microbiol       Date:  2006-10-04       Impact factor: 5.948

5.  Cellular immune responses associated with occult hepatitis C virus infection of the liver.

Authors:  Juan A Quiroga; Silvia Llorente; Inmaculada Castillo; Elena Rodríguez-Iñigo; Margarita Pardo; Vicente Carreño
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

6.  Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay.

Authors:  M T Shata; A Barrett; N J Shire; S F Abdelwahab; M Sobhy; E Daef; S S El-Kamary; M Hashem; R E Engle; R H Purcell; S U Emerson; G T Strickland; K E Sherman
Journal:  J Immunol Methods       Date:  2007-09-19       Impact factor: 2.303

7.  Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates.

Authors:  Perdita Wietzke-Braun; Larissa-Bettina Manhardt; Albert Rosenberger; Angela Uy; Giuliano Ramadori; Sabine Mihm
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

Review 8.  Vaccination for hepatitis C virus: closing in on an evasive target.

Authors:  John Halliday; Paul Klenerman; Eleanor Barnes
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

9.  Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection.

Authors:  Yves Rivière; Thomas Montange; Geneviève Janvier; Caroline Marnata; Ludovic Durrieu; Marie-Laure Chaix; Maria Isaguliants; Odile Launay; Jean-Louis Bresson; Stanislas Pol
Journal:  Virol J       Date:  2012-03-28       Impact factor: 4.099

10.  Two distinct functional patterns of hepatitis C Virus (HCV)-specific T cell responses in seronegative, aviremic patients.

Authors:  Yoon Seok Choi; Jung Eun Lee; Seung Joo Nam; Jung Tak Park; Hyon-Suk Kim; Kyu Hun Choi; Beom Seok Kim; Eui-Cheol Shin
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.